Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Susheel Kodali Added: 8 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more
Author(s): Julien Dreyfus Added: 1 month ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating… View more
Author(s): Gagan Singh Added: 1 month ago
EuroPCR25 - Two-year data confirms sustained benefits of TriClip for severe tricuspid regurgitation.We are joined by Dr Gagan Singh (UC Davis Medical Center, Sacramento, CA, US) to discuss key findings from the TRILUMINATE pivotal trial. This randomised controlled trial compared the TriClip device against medical therapy in symptomatic patients with severe tricuspid regurgitation (TR) who are at… View more
Author(s): Fedrico de Marco Added: 1 month ago
EuroPCR 2025 - Outcomes from the FATE Registry show coapttion gaps are at the upper limit of treatability in this patient group using current tTEER devices.Dr Fedrico de Marco (Centro Cardiologico Monzino IRCCS, Milan, IT) joins us to discuss the management and outcomes from the FATE registry, which investigated 123 case of failed tricuspid transcatheter edge-to-edge repair (tTEER) with all… View more
Author(s): Thomas Modine Added: 1 month ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more
Dr Fabien Praz is an interventional cardiologist at Bern University Hospital, Switzerland. His top areas of expertise are Mitral Valve Regurgitation, Tricuspid Regurgitation, Mitral Stenosis, and Aortic Valve Stenosis. View more
Job title: Professor of Cardiology
Denisa Muraru is a Cardiologist at Istituto Auxologico Italiano, IRCCS and Associate Professor at University of Milano-Bicocca(Milan, Italy).She is an international expert in 3D and strain echocardiography, and the EACVI Vice-President for Echocardiography (2022-2024). Prof Muraru’s main research interests are right heart imaging and tricuspid regurgitation. View more
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
What are the top late-breaking trials from #TCT2023? TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the… View more